Clinical Trial Update: A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating safety and efficacy of 6 mg and 12 mg Telapristone Acetate (Proellex) in premenopausal women with symptomatic uterine fibroi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Proellex (telapristone acetate)

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Uterine Fibroids | Phase 2 | Status: COMPLETED | Results posted: 2019-06-19